Boston Scientific Begins Study of Drug-Eluting Stents in Women and Minorities

oday Boston Scientific enrolled its first patient in a new trial, dubbed PLATINUM Diversity trial, which will enroll up to 1,500 patients from these under-represented populations, specifically: Female, Black of African Heritage, Hispanic/Latino, American Indian or Alaska native. The trial will measure the performance of its drug-eluting stent, the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, in these groups. The principal investigators for the PLATINUM Diversity trial are Roxana Mehran, MD of Mount Sinai School of Medicine n New York, and Wayne Batchelor, MD of Tallahassee Memorial Hospital in Florida.

http://www.ptca.org/news/2014/1020_BSX_PLATINUM_DIVERSITY.html

Source: News from Angioplasty.Org - October 20, 2014 Category: Cardiology Source Type: news